---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261689"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:55:20.471337+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q3 net loss $22.0M; cash $77.7M, runway into H2 2026

## Summary
- Net loss $22.0M ($0.35/share) for Q3 2025, vs $21.2M loss in Q3 2024.
- Cash and equivalents $77.7M; expected to fund operations into H2 2026.
- R&D expenses $17.8M; increase in MICVO costs offset by pause of PYX-106 program.
- Preliminary Phase 1 data for micvotabart pelidotin (MICVO) in HNSCC expected in Q4 2025.
- Translational data presented at ESMO and AACR-NCI-EORTC on MICVO's three mechanisms of action.

## SEC filing metadata
- accession: 0001193125-25-261689
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312525261689/0001193125-25-261689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312525261689/pyxs-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261689
- JSON: https://secwatch.observer/filing/0001193125-25-261689.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.